Search Results

Zentalis ® Pharmaceuticals, Inc. today announced that Zentalis management is scheduled to participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET.

May 30, 2024

·

2 min read

Press Releases

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

January 29, 2025

·

13 min read

Press Releases

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 2, 2025

January 3, 2025

·

2 min read

Drug Development

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

Zentalis ® Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors.

June 18, 2024

·

7 min read

Press Releases

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

January 9, 2025

·

8 min read

Biotech Beach

Zentalis Pharmaceuticals to Participate in Upcoming March 2024 Investor Conferences

Zentalis® Pharmaceuticals, Inc. announced that Zentalis management will participate in several upcoming investor conferences.

February 28, 2024

·

2 min read

Deals

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 3, 2024

Zentalis ® Pharmaceuticals, Inc. today announced that on June 3, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 20,000 shares of the Company’s common stock.

June 3, 2024

·

2 min read